• Explore /
  • Poster
  • / First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

Abstract Video & Slides Poster

Authors

Alison Schram

Alison M. Schram

Memorial Sloan Kettering Cancer Center, New York, NY

Alison M. Schram , Suneel Deepak Kamath , Anthony B. El-Khoueiry , Mitesh J. Borad , Kabir Mody , Amit Mahipal , Lipika Goyal , Vaibhav Sahai , Oleg Schmidt-Kittler , Jinshan Shen , Kai Yu Jen , Alicia Deary , Cori Ann Sherwin , Mahesh Padval , Beni B. Wolf , Vivek Subbiah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT04526106

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4165)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4165

Abstract #

TPS4165

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jayesh Desai

First Author: Shunsuke Kondo

First Author: Michael S. Gordon

Poster

2021 ASCO Annual Meeting

Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).

Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).

First Author: Teresa Macarulla